You learned hypertension management under one guideline. You will likely be tested under another. In August 2025, the AHA and ACC released a new blood pressure guideline that replaced the risk calculator, removed race from first-line drug selection, and changed how stage 2 treatment starts. Most prep materials have not caught up. This review gives you the four testable changes, the stable core that did not move, and the distractor patterns that exam writers build from outdated habits.
\n\nLook at the full title of the guideline: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM. The third organization on that list is AANP. The body that certifies most FNPs co-authored the document, which makes its content fair game for item writers and makes the changes worth your attention now rather than later.
\nHypertension also sits at the intersection of everything the FNP exam rewards: pharmacology, chronic disease management, screening, and patient education. You will see it in vignettes across adult, geriatric, and reproductive-age patients. Knowing exactly where the guideline moved, and where it did not, converts guideline churn from a fear into an advantage over candidates studying from stale notes.
\n\n\nWhen your review course disagrees with the newest guideline: item banks update on a lag, so most questions are written where old and new guidance agree. Master the stable core first. Then learn the deltas, because new items get written at exactly those points of change. When two sources conflict, study to the newest national guideline.
Start with what the 2025 guideline kept, because this is where most of your points live. The BP categories are unchanged: normal is below 120/80, elevated is 120 to 129 with diastolic below 80, stage 1 is 130 to 139 or 80 to 89, and stage 2 is 140/90 or higher. The treatment goal for most adults remains below 130/80. And the four first-line drug classes are the same: thiazide-type diuretics, ACE inhibitors, ARBs, and dihydropyridine calcium channel blockers.
\nRisk stratification now runs through the PREVENT calculator, which estimates 10- and 30-year total cardiovascular risk, including heart failure, not just atherosclerotic events. The clinical decision it drives is the one you already know: a patient with stage 1 hypertension and no clinical CVD, diabetes, or CKD starts medication when predicted risk crosses the threshold, now a 10-year CVD risk of 7.5 percent or higher. Below that threshold, stage 1 gets lifestyle therapy and reassessment in three to six months.
\nThe 2017-era recommendation to prefer a CCB or thiazide for Black adults without heart failure or CKD is gone. All patients without a compelling indication can start any of the four first-line classes, chosen on patient-specific factors such as CKD, diabetes with albuminuria, pregnancy potential, electrolytes, and cost or adherence. If an answer choice justifies a drug selection by race alone, that choice is now wrong.
\nFor stage 2 hypertension, the guideline now prefers initiating two first-line agents as a single-pill dual-class combination, such as an ACE inhibitor with a dihydropyridine CCB or with a thiazide. The rationale is adherence and faster time to control. The old pattern of starting one agent and rechecking in a month is no longer the best answer for a patient presenting at 140/90 or above.
\nChronic hypertension in pregnancy is now actively treated to below 140/90, a shift from the older observe-unless-severe posture. Severe-range pressure of 160/110 or higher, confirmed within 15 minutes, requires treatment within 30 to 60 minutes. Preferred agents are labetalol and extended-release nifedipine, with methyldopa as an alternative. ACE inhibitors and ARBs remain contraindicated. The guideline also tells you to counsel patients with hypertension who are pregnant or planning pregnancy on low-dose aspirin to reduce preeclampsia risk.
\n\nQuestion writers do not invent wrong answers from nothing. They harvest them from guidance that used to be correct. That makes guideline transitions productive territory for hard items, and it gives you a concrete way to study: learn the old rule, learn the new rule, and you can see the trap being set.
\nA 52-year-old woman presents for follow-up. Properly measured office readings average 144/92 today and 146/90 three weeks ago. She has no diabetes, CKD, or known cardiovascular disease. She takes no medications. What is the best initial management?
\nWalk the chain. Two properly measured averages at or above 140/90 make this stage 2 hypertension, so you do not need a risk calculation to justify drug therapy; the stage alone is the indication. Stage 2 means lifestyle counseling plus pharmacotherapy from the start, and the 2025 guideline prefers a single-pill dual-class combination, for example lisinopril-amlodipine or lisinopril-hydrochlorothiazide. Order baseline labs including creatinine, potassium, and a metabolic panel, repeat them within two to four weeks of starting the ACEI and diuretic, and see her back in about a month, titrating until she holds below 130/80.
\n\n\nExam pearl: risk calculators decide treatment in stage 1. Stage 2 is its own indication. If the vignette gives you readings at or above 140/90, do not spend time hunting for risk percentages; pick the answer that starts combination therapy alongside lifestyle change.
Compelling indications override the open-choice rule, and they did not change in spirit. These pairings remain the highest-yield hypertension facts on the exam.
\n| Clinical context | Preferred agent(s) | Why it is tested |
|---|---|---|
| CKD with albuminuria | ACE inhibitor or ARB | Slows progression; classic renal-protection item |
| Diabetes with albuminuria | ACE inhibitor or ARB | Same mechanism; watch for the no-albuminuria twist where any first-line agent works |
| HFrEF | Guideline-directed therapy: ACEI, ARB, or ARNI plus an evidence-based beta-blocker | Avoid non-dihydropyridine CCBs; do not pick verapamil or diltiazem |
| Post-MI or angina | Beta-blocker, usually with an ACEI or ARB | Beta-blockers are not first-line for uncomplicated hypertension, but they are here |
| Pregnancy | Labetalol or extended-release nifedipine; methyldopa as alternative | ACEI, ARB, and renin inhibitors are contraindicated |
Turn this into practice within 24 hours, while the deltas are fresh. Open your question bank, filter to cardiovascular and pharmacology, and run 20 hypertension items. Read every rationale with one question in mind: is this written to the 2025 guideline or to the 2017 one? Flag any rationale that selects drugs by race, reaches for the Pooled Cohort Equations, or starts stage 2 with monotherapy. That single filtering habit builds the exact discrimination the exam is testing.
\nThen self-check without notes: name the four first-line classes, the stage 1 drug-therapy triggers, the stage 2 initiation strategy, the pregnancy-safe agents, and the five compelling-indication pairings. If you can produce those cold, hypertension items stop being a threat and start being banked points.
\nWhen you are ready to drill, run a focused cardiovascular set in FNP Mastery and read the rationales for guideline vintage the same way.
","body_text":null,"og":{"title":"Hypertension on the FNP Exam: 2025 Guideline Changes","description":"The 2025 AHA/ACC guideline changed risk calculation, first-line selection, and stage 2 treatment. What FNP candidates should know before test day.","image":"https://res.cloudinary.com/hlt-media/image/upload/f_auto,q_auto,dpr_auto,c_fill,g_auto,ar_40:21,w_1200/v1781194038/hlt-mmm2/generated/mmm2-flat-vector-editorial-illustration-for-mq9oxvnu.webp"}}